NEW YORK, NY--(Marketwire - Apr 26, 2011) - Taglich Brothers, Inc. is pleased to announce thatDenis Burger. Ph.D., Executive Chairman of BioCurex Inc. (
About Taglich Brothers
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
BioCurex Inc.
BioCurex Inc. is a biotechnology company focused on developing and commercializing products for early cancer diagnosis using a proprietary blood test based on the RECAF™ tumor marker. The test can be carried out in clinical labs or at the doctor's office in a 'rapid test' format similar to pregnancy tests available in drug stores. The assay can also be used for monitoring the recurrence of cancer. Recently, our subsidiary OncoPet Diagnostics Inc. launched a veterinary version of the RECAF™ blood test for companion animals. We have developed and own, royalty-free, the proprietary technology related to the RECAF™ marker, with patents granted in the United States, Australia, Norway, Europe and China and patents applied for and pending in other major worldwide markets. We have licensed our technology to Abbott Labs and Inverness Medical Innovations, two multibillion dollar diagnostic companies with worldwide commercial penetration. BioCurex Inc. is incorporated in Texas and has two subsidiaries: "BioCurex China", located in Shanghai, and "OncoPet Diagnostics", a USA company dedicated to the veterinary uses of our technology.
Contact Information:
Contact:
Taglich Brothers
Karen Payne
Symposia Events
212-779-2971